Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors

STOCK QUOTE

PRESS RELEASES

Recent News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

2014 Press Releases

11-25-2014 ImmuCell To Present at LD Micro Conference on December 2, 2014

11-12-2014 ImmuCell Announces Financial Results for Third Quarter of 2014

11-3-2014 ImmuCell to Announce Third Quarter Fiscal Year 2014 Financial Results

9-17-2014 ImmuCell Participating At Multiple Dairy and Beef Industry Events Throughout September 2014

8-12-2014 ImmuCell Announces Financial Results for the Second Quarter of 2014

7-15-2014 ImmuCell Initiates Pivotal Effectiveness Study to Prevent Calf Scours Caused by Rotavirus

7-9-2014 ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out®

5-13-2014 ImmuCell Announces Results for the First Quarter of 2014

4-10-2014 ImmuCell Retains Lytham Partners to Conduct National Investor Relations Program

3-20-2014 Paul R. Wainman Joins Board of Directors of ImmuCell Corporation

2-13-2014 ImmuCell Announces Increase in Product Sales and Other Annual Financial Results

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700

Contact Us

56 Evergreen Drive
Portland, ME 04103

Office: 207.878.2770

Sales: 1.800.IMMUCELL

mail@immucell.com

NASDAQ: ICCC

Privacy Policy
Terms of Use

Recent News

04-08-25 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

04-07-25 ImmuCell Hires Chief Financial Officer

04-02-25 ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Follow Us

Find us on:

Facebook page opens in new windowYouTube page opens in new window
Copyright © 2020 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales Team
  • Distributors
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset